Humana (HUM) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Illumina (ILMN) has outperformed Humana (HUM) over the past year, gaining 177.0% versus a gain of 34.3%. Over five years, HUM leads with a -10.1% price change compared with -32.9% for ILMN. Humana is the larger company by market cap ($47.61 billion vs $40.43 billion), about 1.2 times the size.
On valuation, Humana trades at a lower forward P/E (23.9x vs 43.8x for Illumina). Humana pays a dividend yielding 0.89%, while Illumina does not currently pay one. Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | ILMN |
|---|---|---|
| Share price | $396.51 | $267.76 |
| Market cap | $47.61B | $40.43B |
| 1-day change | -1.92% | -2.11% |
| YTD return | +54.81% | +104.15% |
| 1-year return | +34.30% | +176.95% |
| 5-year return | -10.09% | -32.85% |
| P/E ratio (TTM) | 37.48 | 49.96 |
| Forward P/E | 23.90 | 43.83 |
| EPS (TTM) | $10.58 | $5.36 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $3.54 | $0.00 |
| Revenue (latest FY) | $129.66B | $4.34B |
| Revenue growth (YoY) | +10.11% | -0.66% |
| Net income (latest FY) | $1.19B | $850.00M |
| Gross margin | — | 66.08% |
| Operating margin | 2.09% | 18.58% |
| Net margin | 0.92% | 19.57% |
| 52-week high | $428.88 | $309.35 |
| 52-week low | $163.11 | $88.00 |
| Distance from 52-week high | -7.55% | -13.44% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +6.87% | -16.40% |
| Average volume | 1.23M | 2.66M |
| Shares outstanding | 120.08M | 151.00M |
| Employees | 67,060 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed HUM by 142.7 percentage points over the past year.
- Illumina trades at a higher earnings multiple (50.0x vs 37.5x trailing P/E).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 0.9 cents for Humana.
- Humana grew revenue faster in its latest fiscal year (+10.11% vs -0.66%).
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
HUM vs ILMN FAQ
Which is bigger, Humana or Illumina?
Humana (HUM) is larger, with a market capitalization of $47.61B compared with $40.43B for Illumina (ILMN).
Which stock has performed better over the past year, HUM or ILMN?
ILMN returned +176.95% over the past 12 months, compared with +34.30% for HUM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HUM or ILMN?
HUM has the lower trailing P/E at 37.5, versus 50.0 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Humana or Illumina?
Humana pays a dividend yielding 0.89%, while Illumina does not currently pay a regular dividend.
Are Humana and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.